Biofrontera Inc. (NASDAQ:BFRI - Get Free Report) was the target of a significant decline in short interest during the month of March. As of March 15th, there was short interest totalling 84,200...
WOBURN, MA / ACCESSWIRE / March 26, 2024 / Biofrontera, Inc. (NASDAQ:BFRI) (the 'Company'), a biopharmaceutical company specializing in the commercialization of dermatological products, today...
(This release corrects the release that was posted earlier on March 15, 2024 to update the Consolidated Balance Sheets)Conference call begins at 10:00 a.m. Eastern time on Monday, March 18...
Conference call begins at 10:00 a.m. Eastern time on Monday, March 18, 2024WOBURN, MA / ACCESSWIRE / March 15, 2024 / Biofrontera, Inc. (NASDAQ:BFRI) (the 'Company'), a biopharmaceutical company...
WOBURN, MA / ACCESSWIRE / March 8, 2024 / Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced that it will...
Biofrontera Inc. (NASDAQ:BFRI Free Report) Analysts at Roth Capital issued their FY2028 earnings estimates for shares of Biofrontera in a research note issued to investors on...
Company closed financing of $8.0 million with an additional $8.0 million second tranche tied to milestones for aggregate proceeds of $16 million gross priced at market per Nasdaq rulesFunding and...
Biofrontera announced it has entered into a securities purchase agreement with healthcare-focused institutional investors led by Rosalind Advisors. Pursuant to the securities purchase agreements, the...
Ameluz (R) transfer price to Biofrontera AG reduced significantlyControl of all US clinical trials of Ameluz transfers to Biofrontera Inc. on June 1WOBURN, MA / ACCESSWIRE / February 20, 2024...